A Stehr1, F Ploner2, I Tugtekin3, M Matejovic4, M Theisen3, C Zülke5, M Georgieff3, P Radermacher3, K-W Jauch5. 1. Klinik und Poliklinik für Chirurgie, Universitätsklinikum, 93053, Regensburg, Germany. alexander.stehr@klinik.uni-regensburg.de. 2. Abteilung für Anästhesie, Landeskrankenhaus, 39049, Sterzing/Südtirol, Italy. 3. Sektion Anästhesiologische Pathophysiologie und Verfahrensentwicklung, Universitätsklinik für Anästhesiologie, 89073, Ulm, Germany. 4. Interni Kliniky, Karlova Univerzita, 30460, Plzen, Czech Republic. 5. Klinik und Poliklinik für Chirurgie, Universitätsklinikum, 93053, Regensburg, Germany.
Abstract
OBJECTIVE: To investigate the effects of combined selective inducible nitric oxide synthase (iNOS) inhibition using 1400 W with nicotinamide (NAD) as a PARS-inhibitor on hepato-splanchnic hemodynamics, O(2) kinetics, and energy metabolism during hyperdynamic porcine endotoxemia. DESIGN: Prospective, randomized, controlled, interventional experiment. SETTING: Animal research laboratory. SUBJECTS: Seventeen domestic pigs. INTERVENTIONS: After 12 h of continuous i.v. endotoxin (LPS) infusion 17 pigs received either no drug (CON, n=9) or 1400 W, titrated to maintain mean arterial pressure (MAP) at pre-endotoxin level, plus 10 mg.kg.h NAD ( n=8;). Measurements were obtained before, 12 h, 18 h, and 24 h after starting LPS infusion. MEASUREMENTS AND RESULTS: In addition to systemic and pulmonary hemodynamics and gas exchange, we measured hepatic arterial and portal venous blood flow, liver and portal venous drained viscera O(2) exchange, ileal mucosal-arterial PCO(2) gap, and portal as well as hepatic venous lactate/pyruvate ratios. Expired NO and plasma nitrate levels were assessed as a parameter of NO production. Without affecting cardiac output, therapy maintained MAP and blunted the LPS-induced rise in expired NO levels, attenuated the progressive fall in liver lactate clearance, and blunted the impairment of hepato-splanchnic redox state. The rise of ileal mucosal-arterial PCO(2) gap was not influenced. CONCLUSIONS: Combining selective iNOS inhibition with NAD as a PARS blocker may prevent circulatory failure and attenuate the detrimental consequences of LPS in intestinal and hepatocellular energy metabolism. Given the potential hepatotoxicity of high-dose NAD treatment, more potent PARS blockers with higher selectivity might further enhance the benefit of this therapeutic approach.
OBJECTIVE: To investigate the effects of combined selective inducible nitric oxide synthase (iNOS) inhibition using 1400 W with nicotinamide (NAD) as a PARS-inhibitor on hepato-splanchnic hemodynamics, O(2) kinetics, and energy metabolism during hyperdynamic porcine endotoxemia. DESIGN: Prospective, randomized, controlled, interventional experiment. SETTING: Animal research laboratory. SUBJECTS: Seventeen domestic pigs. INTERVENTIONS: After 12 h of continuous i.v. endotoxin (LPS) infusion 17 pigs received either no drug (CON, n=9) or 1400 W, titrated to maintain mean arterial pressure (MAP) at pre-endotoxin level, plus 10 mg.kg.h NAD ( n=8;). Measurements were obtained before, 12 h, 18 h, and 24 h after starting LPS infusion. MEASUREMENTS AND RESULTS: In addition to systemic and pulmonary hemodynamics and gas exchange, we measured hepatic arterial and portal venous blood flow, liver and portal venous drained viscera O(2) exchange, ileal mucosal-arterial PCO(2) gap, and portal as well as hepatic venous lactate/pyruvate ratios. Expired NO and plasma nitrate levels were assessed as a parameter of NO production. Without affecting cardiac output, therapy maintained MAP and blunted the LPS-induced rise in expired NO levels, attenuated the progressive fall in liver lactate clearance, and blunted the impairment of hepato-splanchnic redox state. The rise of ileal mucosal-arterial PCO(2) gap was not influenced. CONCLUSIONS: Combining selective iNOS inhibition with NAD as a PARS blocker may prevent circulatory failure and attenuate the detrimental consequences of LPS in intestinal and hepatocellular energy metabolism. Given the potential hepatotoxicity of high-dose NAD treatment, more potent PARS blockers with higher selectivity might further enhance the benefit of this therapeutic approach.
Authors: K Träger; P Radermacher; K M Rieger; R Grover; A Vlatten; T Iber; J Adler; M Georgieff; B Santak Journal: Crit Care Med Date: 2000-06 Impact factor: 7.598
Authors: Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet Journal: Intensive Care Med Date: 2004-06-26 Impact factor: 17.440
Authors: Pierre Asfar; Zsolt Iványi; Hendrik Bracht; Balázs Hauser; Antje Pittner; Damian Vassilev; Marek Nalos; Xavier Maurice Leverve; Uwe Bernd Brückner; Peter Radermacher; Gebhard Fröba Journal: Intensive Care Med Date: 2004-03-26 Impact factor: 17.440
Authors: Martin Siegemund; Jasper van Bommel; Lothar A Schwarte; Wolfgang Studer; Thierry Girard; Stephan Marsch; Peter Radermacher; Can Ince Journal: Intensive Care Med Date: 2005-06-15 Impact factor: 17.440
Authors: Alexander Stehr; Franz Ploner; Karl Traeger; Marc Theisen; Carl Zuelke; Peter Radermacher; Martin Matejovic Journal: Intensive Care Med Date: 2005-10-18 Impact factor: 17.440
Authors: Pierre Kyme; Nils H Thoennissen; Ching Wen Tseng; Gabriela B Thoennissen; Andrea J Wolf; Kenichi Shimada; Utz O Krug; Kunik Lee; Carsten Müller-Tidow; Wolfgang E Berdel; W David Hardy; Adrian F Gombart; H Phillip Koeffler; George Y Liu Journal: J Clin Invest Date: 2012-08-27 Impact factor: 14.808
Authors: Sofiya N Micheva-Viteva; Brittany N Ross; Jun Gao; Samantha Adikari; Pengfei Zhang; Judith R Mourant; Terry H Wu; James H Werner; Alfredo G Torres; Elizabeth Hong-Geller Journal: Infect Immun Date: 2018-12-19 Impact factor: 3.441
Authors: Jason D Simmons; Glenna J Peterson; Monica Campo; Jenny Lohmiller; Shawn J Skerrett; Sorin Tunaru; Stefan Offermanns; David R Sherman; Thomas R Hawn Journal: J Infect Dis Date: 2020-03-02 Impact factor: 5.226